Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acimtamig - Affimed Therapeutics

Next Previous
Drug Profile

Acimtamig - Affimed Therapeutics

Alternative Names: AFM-13; Anti-CD30 anti-CD16A antibody - Affimed Therapeutics; CD30/CD16A; CD30/CD16A ICE®; TandAb AFM13

Latest Information Update: 11 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Affimed Therapeutics
  • Developer Affimed Therapeutics; The Leukemia & Lymphoma Society; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hodgkin's disease; Peripheral T-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cutaneous T-cell lymphoma; Hodgkin's disease; Mycosis fungoides; Peripheral T-cell lymphoma
  • Phase I/II Anaplastic large cell lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 08 Dec 2024 Adverse events and efficacy data from phase II LuminICE-203 trial in Hodgkin Lymphoma released by Affimed
  • 07 Dec 2024 Efficacy and adverse events data from the phase II LuminICE-203 trial in Hodgkin's disease presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem)
  • 05 Dec 2024 Acimtamig - Affimed Therapeutics receives Regenerative Medicine Advanced Therapy (RMAT) status for Hodgkin's disease (Combination therapy, Second-line therapy or greater) in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top